Brian N. Lundstrom, M.D., Ph.D.

The purpose of this study is to demonstrate that RAP-219 is effective in reducing frequency of RNSrecorded long episodes in participants with focal onset seizure.

The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up in different geographic populations.

The purpose of this study is to test different stimulation parameter sets and evaluate patient outcomes.

The purpose of this study is determine the feasibility and efficacy of at-home Transcranial Direct Current Stimulation (tDCS) therapy for focal epilepsy.

The purpose of this study is to evaluate effectiveness, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an addietional 10 weeks post treatment. Quality of Life questionnaires and adverse events will be collected and evaluated.

The overall purpose of this study is to evaluate the effectiveness and safety of brain stimulation techniques currently used for clinical patient care. To determine the likelihood of improvements in seizure frequency, neurological symptoms, and quality of life after treatment with brain stimulation in certain populations, as well as evaluate for any beneficial or deleterious side effects from these modalities. In addition, in instances were brain stimulation was used for diagnostic purposes such as with cortical mapping via TMS, outcomes will be compared to other results already available in the electronic medical record system (e.g., MRI).

The purpose of this study is to demonstrate that the RNS® system is safe and effective as an adjunctive therapy in individuals age 12 through 17 with medically refractory partial onset epilepsy.